Skip to content
Menu

MapLight Therapeutics Q3 EPS $(0.97) Beats $(1.16) Estimate

Benzinga Newsdesk 2 hours ago

NewsEarningsEarnings Beats

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.16) by 16.38 percent. This is a 97.39 percent increase over losses of $(37.18) per

MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.16) by 16.38 percent. This is a 97.39 percent increase over losses of $(37.18) per share from the same period last year.

Read at benzinga.com